US based biotechnology company Amgen has announced plans to establish a new Science & Innovation Centre at Genome Valley in Hyderabad, strengthening the city’s position as a global hub for pharmaceutical research, biotechnology and drug discovery.
The new centre is expected to become operational in 2027 and will become part of Amgen’s global research and development network, which currently includes seven research laboratories worldwide.
Focus on drug discovery and advanced research
- The Hyderabad centre will bring together experimental science, advanced technology and digital capabilities to support Amgen’s global research programmes.
- Its work is expected to cover areas including discovery chemistry, drug metabolism, pharmacokinetics and precision medicine. The centre will also contribute to the development of new approaches for discovering and developing medicines.
- Amgen said the facility will complement its existing technology and innovation operations in Hyderabad, creating a stronger research and technology presence in the city.
Hyderabad strengthens its global R&D position
- The announcement is significant for Hyderabad’s growing life sciences ecosystem.
- Genome Valley has developed into a major cluster for biotechnology, pharmaceuticals, vaccines and research. The region hosts a large number of life sciences companies and research facilities, making it an attractive location for global pharmaceutical and biotechnology companies.
- Amgen’s decision to establish a dedicated science and innovation facility further strengthens Hyderabad’s role beyond pharmaceutical manufacturing, particularly in high value research and development.
Part of Amgen’s global research network
- The new Hyderabad centre will join Amgen’s existing network of research laboratories around the world.
- The company sees India as an important part of its global research and innovation strategy. The Hyderabad facility is expected to support collaboration between scientists in India and Amgen’s international research teams.
- The centre is also expected to benefit from Hyderabad’s availability of specialised scientific talent and its established pharmaceutical and biotechnology ecosystem.
Telangana welcomes the investment
- Telangana officials have welcomed the announcement, describing it as further evidence of Hyderabad’s growing importance in global life sciences research.
- The state has been working to expand Hyderabad’s position as a centre for research, innovation, biotechnology and advanced pharmaceutical development.
- The Telangana Life Sciences Policy 2026-2030 identifies Hyderabad as a major destination for global innovation centres operated by international healthcare and life sciences companies.
Expected impact on Hyderabad
- The project could have wider benefits for Hyderabad’s life sciences sector by strengthening demand for specialised scientific, technology and research talent.
- It could also encourage greater collaboration between global pharmaceutical companies, research institutions, universities and India’s biotechnology ecosystem.
- Importantly, the announcement represents a shift towards higher value scientific activity, rather than simply expanding manufacturing capacity.
Why Genome Valley matters
- Genome Valley is one of Hyderabad’s most important life-sciences clusters. It has developed around research, drug discovery, vaccines, biologics and pharmaceutical manufacturing.
- Its established infrastructure and concentration of specialised companies have helped attract multinational pharmaceutical and biotechnology companies.
- The addition of Amgen’s new Science & Innovation Centre could further strengthen this ecosystem and increase Hyderabad’s visibility on the global drug discovery map.
What happens next?
Amgen’s new centre is expected to become operational in 2027.
The immediate focus will be on developing the facility and integrating it into Amgen’s worldwide research network. Once operational, the centre is expected to support scientific research and drug development activities alongside Amgen’s existing Hyderabad operations.
